<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Olaniru OE</submitter><funding>European Research Council</funding><funding>Medical Research Council</funding><funding>Diabetes UK</funding><funding>Horizon 2020</funding><pagination>101285</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8326393</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>53</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>Members of the adhesion G protein-coupled receptor (aGPCR) subfamily are important actors in metabolic processes, with GPR56 (ADGRG1) emerging as a possible target for type 2 diabetes therapy. GPR56 can be activated by collagen III, its endogenous ligand, and by a synthetic seven amino-acid peptide (TYFAVLM; P7) contained within the GPR56 Stachel sequence. However, the mechanisms regulating GPR56 trafficking dynamics and agonist activities are not yet clear.&lt;h4>Methods&lt;/h4>Here, we introduced SNAPf-tag into the N-terminal segment of GPR56 to monitor GPR56 cellular activity in situ. Confocal and super-resolution microscopy were used to investigate the trafficking pattern of GPR56 in native MIN6 β-cells and in MIN6 β-cells where GPR56 had been deleted by CRISPR-Cas9 gene editing. Insulin secretion, changes in intracellular calcium, and β-cell apoptosis were determined by radioimmunoassay, single-cell calcium microfluorimetry, and measuring caspase 3/7 activities, respectively, in MIN6 β-cells and human islets.&lt;h4>Results&lt;/h4>SNAP-tag labelling indicated that GPR56 predominantly underwent constitutive internalisation in the absence of an exogenous agonist, unlike GLP-1R. Collagen III further stimulated GPR56 internalisation, whereas P7 was without significant effect. The overexpression of GPR56 in MIN6 β-cells did not affect insulin secretion. However, it was associated with reduced β-cell apoptosis, while the deletion of GPR56 made MIN6 β-cells more susceptible to cytokine-induced apoptosis. P7 induced a rapid increase in the intracellular calcium in MIN6 β-cells (in a GPR56-dependent manner) and human islets, and it also caused a sustained and reversible increase in insulin secretion from human islets. Collagen III protected human islets from cytokine-induced apoptosis, while P7 was without significant effect.&lt;h4>Conclusions&lt;/h4>These data indicate that GPR56 exhibits both agonist-dependent and -independent trafficking in β-cells and suggest that while GPR56 undergoes constitutive signalling, it can also respond to its ligands when required. We have also identified that constitutive and agonist-dependent GPR56 activation is coupled to protect β-cells against apoptosis, offering a potential therapeutic target to maintain β-cell mass in type 2 diabetes.</pubmed_abstract><journal>Molecular metabolism</journal><pubmed_title>SNAP-tag-enabled super-resolution imaging reveals constitutive and agonist-dependent trafficking of GPR56 in pancreatic β-cells.</pubmed_title><pmcid>PMC8326393</pmcid><funding_grant_id>17/0005600</funding_grant_id><funding_grant_id>MR/N00275X/1</funding_grant_id><funding_grant_id>MR/S025618/1</funding_grant_id><funding_grant_id>17/0005681</funding_grant_id><funding_grant_id>715884</funding_grant_id><pubmed_authors>King AJF</pubmed_authors><pubmed_authors>Arvaniti A</pubmed_authors><pubmed_authors>Broichhagen J</pubmed_authors><pubmed_authors>Olaniru OE</pubmed_authors><pubmed_authors>Ast J</pubmed_authors><pubmed_authors>Jones PM</pubmed_authors><pubmed_authors>Persaud SJ</pubmed_authors><pubmed_authors>Atanes P</pubmed_authors><pubmed_authors>Hodson DJ</pubmed_authors><pubmed_authors>Huang GC</pubmed_authors><pubmed_authors>Cheng J</pubmed_authors></additional><is_claimable>false</is_claimable><name>SNAP-tag-enabled super-resolution imaging reveals constitutive and agonist-dependent trafficking of GPR56 in pancreatic β-cells.</name><description>&lt;h4>Objective&lt;/h4>Members of the adhesion G protein-coupled receptor (aGPCR) subfamily are important actors in metabolic processes, with GPR56 (ADGRG1) emerging as a possible target for type 2 diabetes therapy. GPR56 can be activated by collagen III, its endogenous ligand, and by a synthetic seven amino-acid peptide (TYFAVLM; P7) contained within the GPR56 Stachel sequence. However, the mechanisms regulating GPR56 trafficking dynamics and agonist activities are not yet clear.&lt;h4>Methods&lt;/h4>Here, we introduced SNAPf-tag into the N-terminal segment of GPR56 to monitor GPR56 cellular activity in situ. Confocal and super-resolution microscopy were used to investigate the trafficking pattern of GPR56 in native MIN6 β-cells and in MIN6 β-cells where GPR56 had been deleted by CRISPR-Cas9 gene editing. Insulin secretion, changes in intracellular calcium, and β-cell apoptosis were determined by radioimmunoassay, single-cell calcium microfluorimetry, and measuring caspase 3/7 activities, respectively, in MIN6 β-cells and human islets.&lt;h4>Results&lt;/h4>SNAP-tag labelling indicated that GPR56 predominantly underwent constitutive internalisation in the absence of an exogenous agonist, unlike GLP-1R. Collagen III further stimulated GPR56 internalisation, whereas P7 was without significant effect. The overexpression of GPR56 in MIN6 β-cells did not affect insulin secretion. However, it was associated with reduced β-cell apoptosis, while the deletion of GPR56 made MIN6 β-cells more susceptible to cytokine-induced apoptosis. P7 induced a rapid increase in the intracellular calcium in MIN6 β-cells (in a GPR56-dependent manner) and human islets, and it also caused a sustained and reversible increase in insulin secretion from human islets. Collagen III protected human islets from cytokine-induced apoptosis, while P7 was without significant effect.&lt;h4>Conclusions&lt;/h4>These data indicate that GPR56 exhibits both agonist-dependent and -independent trafficking in β-cells and suggest that while GPR56 undergoes constitutive signalling, it can also respond to its ligands when required. We have also identified that constitutive and agonist-dependent GPR56 activation is coupled to protect β-cells against apoptosis, offering a potential therapeutic target to maintain β-cell mass in type 2 diabetes.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2024-11-21T07:35:13.967Z</modification><creation>2022-02-11T04:28:18.879Z</creation></dates><accession>S-EPMC8326393</accession><cross_references><pubmed>34224919</pubmed><doi>10.1016/j.molmet.2021.101285</doi></cross_references></HashMap>